International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

Hillengass J, Usmani S, Rajkumar SV, Durie BG, Mateos MV, Lonial S, Joao C, Anderson KC, García-Sanz R, Serra ER, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen WM, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S (2019)

Publication Type: Journal article, Review article

Publication year: 2019

Journal

Book Volume: 20

Pages Range: e302-e312

Journal Issue: 6

DOI: 10.1016/S1470-2045(19)30309-2

Abstract

Recent advances in the treatment of multiple myeloma have increased the need for accurate diagnosis of the disease. The detection of bone and bone marrow lesions is crucial in the investigation of multiple myeloma and often dictates the decision to start treatment. Furthermore, detection of minimal residual disease is important for prognosis determination and treatment planning, and it has underscored an unmet need for sensitive imaging methods that accurately assess patient response to multiple myeloma treatment. Low-dose whole-body CT has increased sensitivity compared with conventional skeletal survey in the detection of bone disease, which can reveal information leading to changes in therapy and disease management that could prevent or delay the onset of clinically significant morbidity and mortality as a result of skeletal-related events. Given the multiple options available for the detection of bone and bone marrow lesions, ranging from conventional skeletal survey to whole-body CT, PET/CT, and MRI, the International Myeloma Working Group decided to establish guidelines on optimal use of imaging methods at different disease stages. These recommendations on imaging within and outside of clinical trials will help standardise imaging for monoclonal plasma cell disorders worldwide to allow the comparison of results and the unification of treatment approaches for multiple myeloma.

Involved external institutions

Roswell Park Cancer Institute United States (USA) (US) Carolinas HealthCare System United States (USA) (US) Hospital de Clínicas Dr. Manuel Quintela Uruguay (UY) Shanghai Changzheng Hospital China (CN) Amsterdam University Medical Centers (Amsterdam UMC) / Amsterdam Universitair Medische Centra Netherlands (NL) Sarah Cannon Research Institute (SCRI) United States (USA) (US) University of Bologna / Università di Bologna Italy (IT) Mayo Clinic United States (USA) (US) Clínica Universidad de Navarra Spain (ES) Universitätsklinikum Heidelberg Germany (DE) Memorial Sloan Kettering Cancer Center United States (USA) (US) Universitair Ziekenhuis Brussel Belgium (BE) Universitätsklinikum Würzburg Germany (DE) Oslo University Hospital / Oslo Universitetssykehus Rikshospitalet Norway (NO) Beijing Chao-Yang Hospital / 北京朝阳医院 China (CN) University of Southern Denmark / Syddansk Universitet Denmark (DK) University of Rochester (UR) United States (USA) (US) Poznan University of Medical Sciences / Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu Poland (PL) Boston University United States (USA) (US) Columbia University United States (USA) (US) Cedars-Sinai Medical Center United States (USA) (US) Complejo Hospitalario de Salamanca / Complejo Asistencial Universitario de Salamanca Spain (ES) Emory University United States (USA) (US) New University of Lisbon / Universidade Nova de Lisboa Portugal (PT) Dana–Farber Cancer Institute United States (USA) (US) Massachusetts General Hospital United States (USA) (US) Wiener Gesundheitsverbund Kliniken Austria (AT)

How to cite

APA:

Hillengass, J., Usmani, S., Rajkumar, S.V., Durie, B.G., Mateos, M.V., Lonial, S.,... Lentzsch, S. (2019). International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncology, 20(6), e302-e312. https://doi.org/10.1016/S1470-2045(19)30309-2

MLA:

Hillengass, Jens, et al. "International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders." Lancet Oncology 20.6 (2019): e302-e312.

BibTeX: Download